Related coverage linked through entity extraction aliases.
Apr 07, 2026
President Donald Trump’s April 2, 2026 proclamation sets a 100% Section 232 tariff on certain patented pharmaceuticals and APIs from July 31, 2026. Generics, biosimilars and several specialty categories are exempt, while some companies can qualify for reduced or zero tariffs through onshoring or MFN pricing agreements.
Feb 23, 2026
A 6-3 Supreme Court decision rejected unlimited presidential tariff authority under IEEPA, constraining mega-tariffs while Section 232 pharmaceutical investigations and potential duties on branded medicines remain in effect.
Feb 13, 2026
F3 Tech will lead Maryland's proposal for a $40 million multi-user biomanufacturing facility under the federal BioMADE program, developed with the Maryland Department of Commerce to strengthen the state's biotechnology economy.
